News Focus
News Focus
icon url

alertmeipp

09/29/25 7:38 AM

#5415 RE: DewDiligence #5413

I guess they had to go with that as primary due to sample size?

Somewhat expected but still was hoping for home run
icon url

dewophile

09/29/25 8:18 AM

#5416 RE: DewDiligence #5413

Pfizer was using hospitalization as primary endpoint for their their fusion inhibitor so a signal on that endpoint is great. The concern would be how long it takes to enroll a phase 3 they were planning on 2k and if you limit the study to 75 and up and copd/chf that could take a long time so feasibility issues. Obviously w a 80 percent reduction you wouldn’t need 2k but still that might be a concern for a partner
Nevertheless in the whole very good data IMO
icon url

DewDiligence

09/29/25 9:58 AM

#5420 RE: DewDiligence #5413

Green. Market shaking off kneejerk reaction to missed primary and seeing positives in overall dataset.